PR87109

CAMBRIDGE, England, Dec. 8, 2020 /PRNewswire=KYODO JBN/ --

- State-of-the-art site will enable rapid delivery of engineered cell lines

- Powering ready-to-use edited cell-line portfolio expansion

- Enable comprehensive customization for research, diagnostic and therapeutic development

Today Abcam[http://www.abcamplc.com/] (AIM: ABC; NASDAQ: ABCM), a global

innovator in life science reagents and tools, announced the opening of a new

16,000 sq ft purpose-fitted facility in Fremont, CA, which will serve as a

major new site for its specialist cell engineering team. This state-of-the-art

facility will enable delivery of engineered cell lines to power expansion of

the ready-to-use portfolio and facilitate delivery of customization to meet the

demanding needs of research, diagnostic and therapeutic development.

The move follows Abcam's acquisition of the team and its highly adaptable

CRISPR-Cas9-based gene editing platform from Applied Stem Cell earlier this

year. The new facility has received significant investment from the business

and features an extensive suite of tissue culture labs and is a pivotal part of

Abcam's ambitious growth plans to expand and cement its position in the edited

cell line market.

Jac Price, SVP Manufacturing and Supply Chain at Abcam, said: "We are excited

to be part of the active and growing biotech community in Fremont with our

newest, customized facility. Our cell engineering team are highly experienced

and a long-established leader in the edited cell lines market. This facility

will enable them to further expand and increase the provision of a

comprehensive cell engineering service for a variety of different life sciences

applications, at both speed and scale."

This enhanced capability builds upon Abcam's previous acquisition of an

extensive range of knockout cell lines from Edigene [https://www.abcamplc.com/abcam-enters-cell-editing-market-through-acquisition-of-edigenes-knock-out-cell-lines-and-lysates-portfolio/ ]

last year. Ready-made KO cell lines [https://www.abcam.com/reagents/knockout-cell-lines]

play a significant role in the study and understanding of biological pathways

and disease models. Abcam's gene-edited cell line portfolio and engineering

capability is also supporting the company's award-winning knockout validation

initiative [https://www.abcam.com/index.html?pageconfig=news&rid=17083], an

integral part of the organization's ongoing efforts to raise reagent quality

standards across the industry.

Notes to Editors

About Abcam plc

As a global life sciences company, Abcam identifies, develops, and distributes

high-quality biological reagents and tools that are crucial to research, drug

discovery and diagnostics. Working across the industry, the Company supports

life scientists to achieve their mission, faster.

Abcam partners with life science organizations to co-create novel binders for

use in drug discovery, in vitro diagnostics and therapeutics, driven by the

Company's proprietary discovery platforms and world-leading antibody expertise.

By constantly innovating its binders and assays, Abcam is helping advance the

global understanding of biology and causes of disease, which enables new

treatments and improved health. The Company's pioneering data-sharing approach

gives scientists increased confidence in their results by providing validation,

user comments and peer-reviewed citations for its 110,000 products.

With 13 sites globally, many of Abcam's 1,500-strong team are located in the world's

leading life science research hubs, complementing a global network of services and support.

To find out more, please visit www.abcam.com and www.abcamplc.com.

Logo - https://mma.prnewswire.com/media/1061261/Abcam_Logo.jpg

Source: Abcam